Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 5, 2002, Pages 1553-1556

  Gershon, Andrea S ^a   De Azavedo, Joyce C S ^a   McGeer, Allison ^a   Ostrowska, Krystyna I ^a   Church, Deirdre ^a   Hoban, Daryl J ^a   Harding, Godfrey K M ^a   Weiss, Karl ^a   Abbott, Lewis ^a   Smaill, Fiona ^a   Gourdeau, Marie ^a   Murray, Gilles ^a   Low, Donald E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CETHROMYCIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CANADA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BLOOD; CANADA; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 0036233721     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.5.1553-1556.2002     Document Type: Article

References (22)

1. Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer
2. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada
3. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada
4. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America
5. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States
6. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer
7. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients
8. Bacteremia due to vancomycin-resistant enterococci in neutropenic cancer patients
9. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin
10. False resistance to imipenem with a microdilution susceptibility testing system
11. In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci
12. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
13. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility, of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
14. Antibiotic susceptibility of streptococci isolated from blood from neutropenic patients
15. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: Analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis
16. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis
17. Antimicrobial susceptibility of viridans group streptococci
18. Beta-lactam stability, in frozen microdilution PASCO MIC panels using strains with known resistance mechanisms as biosensors
19. Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients
20. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents